Astrazeneca (AZN) Net Margin (2009 - 2026)
Astrazeneca (AZN) recorded quarterly Net Margin of 4000.0% in Q1 2026, down 91.34% quarter-over-quarter from 46166.67% in Q4 2025, and down 142838.0% on a YoY basis from N/an in Q1 2025.
Astrazeneca (AZN) Net Margin (2009 - 2026) Analysis & Trends
Astrazeneca's Net Margin history runs 18 years deep, the most recent figure standing at 4000.0% for Q1 2026.
- In Q1 2026, Net Margin fell 142838.0% year-over-year to 4000.0%; the TTM figure through Mar 2026 stood at 11746.08% (up 1068505.0% YoY), while the FY2025 annual figure was 17.41%, down 74478.0% from the prior year.
- Net Margin was 4000.0% for Q1 2026 at Astrazeneca, down from 46166.67% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 48250.0% in Q2 2024 to a low of 12400.0% in Q2 2022.
- Historically, Net Margin has averaged 10709.99% across 5 years, with a median of 4000.0% in 2026.
- The sharpest annual moves came in 2022 and 2024: Net Margin sank 1308000 bps in 2022, then surged 4730803 bps in 2024.
- A 5-year view of Net Margin shows it stood at 1083.54% in 2022, then sank by 41 bps to 642.96% in 2023, then plunged by 71 bps to 184.05% in 2024, then surged by 24984 bps to 46166.67% in 2025, then sank by 91 bps to 4000.0% in 2026.
- The last three Net Margin figures came in at 4000.0% (Q1 2026), 46166.67% (Q4 2025), and 23409.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 23.32% |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | 4,000.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00% |
| Dec 31, 2025 | 46,166.67% |
| Sep 30, 2025 | 23,409.09% |
| Jun 30, 2025 | 44,450.00% |
| Mar 31, 2025 | 5,428.38% |
| Dec 31, 2024 | 184.05% |
| Sep 30, 2024 | 4,498.31% |
| Jun 30, 2024 | 48,250.00% |
| Mar 31, 2024 | 4,842.22% |
| Dec 31, 2023 | 642.96% |
| Sep 30, 2023 | 1,416.49% |
| Jun 30, 2023 | 941.97% |
| Mar 31, 2023 | 8,077.78% |
| Dec 31, 2022 | 1,083.54% |
| Sep 30, 2022 | 921.35% |
| Jun 30, 2022 | -12,400.00% |
| Mar 31, 2022 | 156.98% |
| Dec 31, 2021 | -145.61% |
| Sep 30, 2021 | -1,585.60% |
| Jun 30, 2021 | 680.00% |